Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 3/2008

01.09.2008

Clinical trials and biomarker development with molecularly targeted agents and radiotherapy

verfasst von: Neesha Dhani, Lillian L. Siu

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The conventional paradigm of drug development used for cytotoxic chemotherapeutic agents may not represent the most effective method of assessing the safety and biological activity of molecularly targeted agents, given that the latter may offer improved therapeutic indices with less toxic effects on normal tissues.

Objectives

With the number of novel therapeutics in oncology entering the investigative arena, there is a need to expedite the drug development process by allowing for optimal selection of agents with the greatest likelihood of having clinical benefit over those of lower potential utility.

Discussion

The high throughput techniques now available in genomic, proteomic and metabolomic profiling should allow for more effective preclinical investigation with the identification of biomarkers or indicators of treatment response, leading to increased clinical efficacy with appropriate patient selection.

Conclusion

With this in mind, current investigation should be directed at validating novel endpoints in order to accelerate the drug development and approval process with targeted therapeutics in oncology.
Literatur
1.
Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69, 89–95.CrossRef
2.
Slamon, D. J., Clark, G. M., Wong, S. G., et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177–182.PubMedCrossRef
3.
Ross, J. S., & Fletcher, J. A. (1998). The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist, 3, 237–252.PubMed
4.
Ross, J. S., Fletcher, J. A., Bloom, K. J., et al. (2004). Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics, 3, 379–398.PubMedCrossRef
5.
Hayes, D. F., Thor, A. D., Dressler, L. G., et al. (2007). HER2 and response to paclitaxel in node-positive breast cancer. New England Journal of Medicine, 357, 1496–1506.PubMedCrossRef
6.
7.
Cho, W. C., & Cheng, C. H. (2007). Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics, 4, 401–410.PubMedCrossRef
8.
Claudino, W. M., Quattrone, A., Biganzoli, L., et al. (2007). Metabolomics: available results, current research projects in breast cancer, and future applications. Journal of Clinical Oncology, 25, 2840–2846.PubMedCrossRef
9.
Barthel, H., Perumal, M., Latigo, J., et al. (2005). The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. European Journal of Nuclear Medicine and Molecular Imaging, 32, 257–263.PubMedCrossRef
10.
Fox, E., Curt, G. A., & Balis, F. M. (2002). Clinical trial design for target-based therapy. Oncologist, 7, 401–409.PubMedCrossRef
11.
DiMasi, J. A., & Grabowski, H. G. (2007). Economics of new oncology drug development. Journal of Clinical Oncology, 25, 209–216.PubMedCrossRef
12.
Kummar, S., Gutierrez, M., Doroshow, J. H., et al. (2006). Drug development in oncology: classical cytotoxics and molecularly targeted agents. British Journal of Clinical Pharmacology, 62, 15–26.PubMedCrossRef
13.
Rubio-Viqueira, B., Jimeno, A., Cusatis, G., et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Research, 12, 4652–4661.PubMedCrossRef
14.
Buchler, P., Reber, H. A., Lavey, R. S., et al. (2004). Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. Journal of Surgical Research, 120, 295–303.PubMedCrossRef
15.
Cai, W., Ebrahimnejad, A., Chen, K., et al. (2007) Quantitative radioimmuno PET imaging of EphA2 in tumor-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging, 34, 2024–2036.
16.
Chi, K. N., Eisenhauer, E., Fazli, L., et al. (2005). A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Journal of the National Cancer Institute, 97, 1287–1296.PubMedCrossRef
17.
Lorusso, P. M., Adjei, A. A., Varterasian, M., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology, 23, 5281–5293.PubMedCrossRef
18.
Duran, I., Kortmansky, J., Singh, D., et al. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95, 1148–1154.PubMedCrossRef
19.
The Food and Drug Modernization Act of 1997. (2007). Title 21 Code of Federal Regulations Part 314 Subpart H Section 314.500.
20.
Slamon, D. J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344, 783–792.PubMedCrossRef
21.
Baselga, J., Tripathy, D., Mendelsohn, J., et al. (1999). Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology, 26, 78–83.PubMed
22.
Jiang, W., Freidlin, B., & Simon, R. (2007). Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute, 99, 1036–1043.PubMedCrossRef
23.
Steel, G. G., & Peckham, M. J. (1979). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. International Journal of Radiation Oncology, Biology, Physics, 5, 85–91.PubMed
24.
Overgaard, M., Jensen, M. B., Overgaard, J., et al. (1999). Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet, 353, 1641–1648.PubMedCrossRef
25.
Vaupel, P., & Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Reviews, 26, 225–239.PubMedCrossRef
26.
Rischin, D., Hicks, R. J., Fisher, R., et al. (2006). Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. Journal of Clinical Oncology, 24, 2098–2104.PubMedCrossRef
27.
Overgaard, J., Eriksen, J. G., Nordsmark, M., et al. (2005). Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncology, 6, 757–764.PubMedCrossRef
28.
Koukourakis, M. I., Bentzen, S. M., Giatromanolaki, A., et al. (2006). Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. Journal of Clinical Oncology, 24, 727–735.PubMedCrossRef
29.
Sedelnikova, O. A., Rogakou, E. P., Panyutin, I. G., et al. (2002). Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiation Research, 158, 486–492.PubMedCrossRef
30.
Kakolyris, S., Giatromanolaki, A., Koukourakis, M., et al. (1999). Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). Journal of Pathology, 189, 351–357.PubMedCrossRef
31.
Munshi, A., Tanaka, T., Hobbs, M. L., et al. (2006). Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Molecular Cancer Therapeutics, 5, 1967–1974.PubMedCrossRef
32.
Ang, K. K., Berkey, B. A., Tu, X., et al. (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research, 62, 7350–7356.PubMed
33.
Wiebalk, K., Schmezer, P., Kropp, S., et al. (2007). In vitro radiation-induced expression of XPC mRNA as a possible biomarker for developing adverse reactions during radiotherapy. International Journal of Cancer, 121, 2340–2345.CrossRef
34.
Bentzen, S. M., Harari, P. M., & Bernier, J. (2007). Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nature Clinical Practice Oncology, 4, 172–180.PubMedCrossRef
Metadaten
Titel
Clinical trials and biomarker development with molecularly targeted agents and radiotherapy
verfasst von
Neesha Dhani
Lillian L. Siu
Publikationsdatum
01.09.2008
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 3/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9140-0

Weitere Artikel der Ausgabe 3/2008

Cancer and Metastasis Reviews 3/2008 Zur Ausgabe

OriginalPaper

Molecular markers of radiation-related normal tissue toxicity

OriginalPaper

Clinical biomarkers for hypoxia targeting

OriginalPaper

Preface

OriginalPaper

Multiple biomarker tissue microarrays: bioinformatics and practical approaches

OriginalPaper

Use of palliative radiotherapy trials for clinical biomarker development

OriginalPaper

Clinical biomarkers of kinase activity: examples from EGFR inhibition trials

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise